Semaglutide

GLP-1 S is a medication originally developed to help regulate blood sugar in people with type 2 diabetes. It mimics a natural hormone in the body (GLP-1) that helps control appetite, insulin levels, and digestion. Recently, it has gained significant attention in research for its effects on weight loss and metabolic health.

GLP-1 S is a prescription medication approved for the treatment of type 2 diabetes and weight management. This content is provided for educational purposes only and does not constitute medical advice.

What is Semaglutide?

GLP-1 S is a GLP-1 receptor agonist originally developed to treat type 2 diabetes. It works by mimicking the body's natural GLP-1 hormone to regulate blood sugar, curb appetite, and slow digestion. In recent clinical trials, it has also shown powerful effects on long-term weight loss, leading to its FDA approval under the brand name Wegovy for chronic weight management.

Potential Benefits Shown in Studies

Supporting long-term weight loss
Reducing appetite and food cravings
Controlling blood sugar levels
Slowing digestion to help with fullness
Supporting cardiovascular health
Improving insulin sensitivity
Lowering inflammation in metabolic tissues

Mechanisms of Action

GLP-1 S exerts its effects by:

Activating GLP-1 receptors in the pancreas and brain
Stimulating insulin secretion in response to elevated blood glucose
Suppressing glucagon release, lowering hepatic glucose output
Slowing gastric emptying, which promotes a feeling of fullness
Reducing appetite through action on brain regions that regulate hunger

Research Highlights

Weight Loss Outcomes

In the STEP 1 trial, patients with obesity receiving Semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight in 68 weeks — significantly outperforming the placebo group.

Source: Wilding, J. P. H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity – NEJM.